415 Capital Management GmbH is a specialist investment firm which invests in innovative medical device (“MedTech”) companies in Europe, the United States, and Israel. The firm primarily invests in novel technologies addressing cardiovascular disease, its risk factors and comorbidities. The 415 Capital team has funded over 40 MedTech startups over the past 20 years with successful exits including Claret Medical (sold to Boston Scientific), ReCor Medical (sold to Otsuka Holdings), ImThera Medical (sold to LivaNova), CardiAQ Valve Technologies (sold to Edwards Lifesciences), and CoreValve (sold to Medtronic).